Low Dose Naltrexone Compounding
Pharmaceutical Compounding
Why should I take this course?
Course Lesson
Linda Elsegood
Linda Elsegood is the CEO and founder of the LDN's Research Trust. At the age of 44, she was diagnosed with MS. After three years of relapsing/remitting MS and having attacks every 6 months, she was told she had secondary progressive and there was nothing anyone could do to help her.
She decided to take matters into her own hands and started taking low dose naltrexone in December 2003. After 3 months on LDN, she was told she no longer had secondary progressive MS, and she states, "LDN has given me a better quality of life and hope for the future."
With her success with LDN, she wanted everyone to hear about it as a treatment option. The LDN Research Trust became a UK registered non-profit charity in 2004. Since 2004, Linda has organized 7 conferences, started an LDN radio show, manages their social media channels, created 6 documentaries, and edited the LDN Book's 1 & 2.
The LDN Research Trust aims to initiate clinical trials of Low Dose Naltrexone for autoimmune diseases and cancers. The Trust has helped over 100,000 people all over the world obtain LDN.

Sarah Taylor, PharmaD
Sarah attended undergrad at St. Olaf College in Northfield where she majored in chemistry and worked in a lab synthesizing dendrimers for possible use as pharmaceutical delivery molecules. It was there that she first developed an interest in pharmacy. She graduated from St. Olaf and pursued her interest in pharmacy at the University of Minnesota College of Pharmacy. During school, she began working at a compounding pharmacy utilizing her chemistry and pharmacy background to develop formulas for a myriad of pharmaceutical dosage forms and applications. After graduation, she continued to work at the compounding pharmacy for a total of 5 years. She uses this experience to help with her current position as the manager of Fagron Academy. Her favorite types of compounds to make include tablet triturates and gummies.